Arvinas (ARVN) Amortization of Deferred Charges (2019 - 2021)
Arvinas (ARVN) posted quarterly Amortization of Deferred Charges of $400000.0 for Q1 2026, down 33.33% year-over-year from $600000.0 in Q1 2025, and down 20.0% quarter-over-quarter from $500000.0 in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Amortization of Deferred Charges (2019 - 2021) Analysis & Trends
Arvinas' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $400000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 33.33% year-over-year to $400000.0; the TTM figure through Mar 2026 stood at $2.0 million (down 4.76% YoY), while the FY2025 annual figure was $2.2 million, up 10.0% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $400000.0, down from $500000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $600000.0 in Q1 2022, with the low at $400000.0 in Q2 2022.
- The 5-year median for Amortization of Deferred Charges is $500000.0 (2022), against an average of $494117.6.
- The sharpest annual moves came in 2022 and 2026: Amortization of Deferred Charges jumped 100.0% in 2022, then plunged 33.33% in 2026.
- Arvinas' Amortization of Deferred Charges stood at $400000.0 in 2022, then climbed by 25.0% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025, then slipped by 20.0% to $400000.0 in 2026.
- Business Quant data shows ARVN's Amortization of Deferred Charges at $400000.0 in Q1 2026, $500000.0 in Q4 2025, and $500000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 268,739.00 |
| Sep 30, 2021 | 314,203.00 |
| Jun 30, 2021 | 311,918.00 |
| Mar 31, 2021 | 305,140.00 |
| Dec 31, 2020 | 275,386.00 |
| Sep 30, 2020 | 228,879.00 |
| Jun 30, 2020 | 225,831.00 |
| Mar 31, 2020 | 169,904.00 |
| Dec 31, 2019 | 193,145.00 |
| Sep 30, 2019 | 140,245.00 |
| Jun 30, 2019 | 186,212.00 |
| Mar 31, 2019 | 180,398.00 |